RBRC02344

Information1

Image
BRC No.RBRC02344
TypeTargeted MutationCartagena
SpeciesMus musculus
Strain nameFVB.129P2-Nf2<tm2Gth>
Former Common nameNf2flox2 (FVB)
H-2 Haplotype
ES Cell line
Background strainFVB/NJcl
Appearancealbino [A/A B/B c/c D/D P/P]
Strain developmentDeveloped by Drs. Marco Giovannini and Gilles Thomas in INSERM at 1988. Strain of Origin: 129P2/OlaHsd-Hprt1<b-m3> via HM-1 ES cell line. FVB background.
Strain descriptionNf2, neurofibromatosis 2 is a tumor suppressor gene encoding a putative cytoskeletal associated protein. This conditional knockout mice have a loxP-flanked Nf2 allele. Conditional Nf2 deficient mice can be generated by crossing with tissue-specific Cre mice.
Colony maintenanceSibling Mating (Homozygote x Homozygote, Heterozygote)Homozygous mutant mice are viable and fertile.
ReferencesGenes Dev., 14, 1617-1630 (2000). 10887156

Health Report

Examination Date / Room / Rack2020/07/06Room:4-BRack:K
2020/03/30Room:4-BRack:K
2020/01/27Room:4-BRack:K
2019/11/25Room:4-BRack:K
2019/09/30Room:4-BRack:K
2019/07/29Room:4-BRack:K
2019/05/27Room:4-BRack:K
2019/03/25Room:4-BRack:K

Gene

Gene info
Gene symbolGene nameChr.Allele symbolAllele namePromoter
Nf2neurofibromatosis 211Nf2<tm2Gth>targeted mutation 2, Gilles Thomas

Gene symbolGene nameChr.Allele symbolAllele namePromoter
loxPphage P1 loxP11loxP

Gene symbolGene nameChr.Allele symbolAllele namePromoter
loxPphage P1 loxP11loxP

Information2

Donor DNAphage P1 loxP sites, mouse Nf2 genomic DNA
Research applicationCre/loxP system
Specific Term and ConditionsIn publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of the following literature(s) designated by the DEPOSITOR is requested. Genes Dev., 14, 1617-1630 (2000).In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. RECIPIENT shall keep DEPOSITOR apprised of any results obtained from the BIOLOGICAL RESOURCE in the course of the research, as soon as they are available. Moreover, if the research results in a potential invention or a substance that may have potential commercial value (hereinafter referred as to the "Invention") RECIPIENT will promptly disclose this Invention to DEPOSITOR with samples thereof for DEPOSITOR's internal use.
RECIPIENT and DEPOSITOR will consult together and agree about the possibility of filing one or more patent application to Invention conceived by one or more employees of Recipients that directly arise out of the research. The Parties will negotiate in good faith the conditions of such patent application according to each party's inventiveness contribution in the Invention.
In case of such Invention, patentable or not, reduced in practice or developed in the course of the research that could not have been obtained, reduced to practice or developed but from using the Material and/or Confidential Information, RECIPIENT and DEPOSITOR shall confer with one another as regards licensing and commercialization of such Invention to negotiate in good faith the terms of an institutional agreement as regards said matters.
DepositorMarco Giovannini (INSERM)
Strain Statusan icon for Live miceLive mice
an icon for Frozen embryosFrozen embryos
Strain AvailabilityCryopreserved embryos (within 1 month)
Live mouse (within 1 month)
Additional Info.Genotyping protocol -PCR-

BRC mice in Publications

Ahmad I, Fernando A, Gurgel R, Clark JJ, Xu L, Hansen MR.
Merlin status regulates p75(NTR) expression and apoptotic signaling in Schwann cells following nerve injury.
Neurobiol. Dis. 82 114-22.(2015) 26057084